Seminar topic: Paradox explained: neutrophils enforce chronic immune tolerance via population-wide epigenetic, transcriptional, metabolic and functional adaptations.

Dr. Tirouvanziam obtained an Engineering degree from Agro Paris Tech, a Masters in Lung Physiology from Université Paris XII and PhD in Development Biology also from Agro Paris-Tech, for his work on human xenografts in SCID mice conducted at the Institut d’Embryologie du CNRS et College de France in Nogent-sur-Marne. 

He then pursued postdoctoral studies in Physiology, Genetics, Immunology and Psychiatry at Stanford University in Palo Alto, California, USA, developing a decade-long translational program focused on collection and deep analysis of patient samples, and culminating in phase 2 clinical trials in cystic fibrosis and autism spectrum disorder.

Dr. Tirouvanziam moved to Atlanta in 2011, where his translational research group of 15 members focuses on engineering of the human innate immune system and immunometabolic disease. Main diseases of interest affecting the lung (such as cystic fibrosis, COVID-19, and tuberculosis), and other organs systems (diabetes, cold tumors, malaria).